Guided Therapeutics, Inc. filed a Form 10-Q with the SEC on November 16, 2026, covering the quarterly period ended September 30, 2026, reporting financial results and balance sheet data for the three and nine months ended on that date.
Key Highlights
- Net loss of $1,825 thousand for the nine months ended September 30, 2026, compared to a net loss of $1,978 thousand for the same period in 2025, according to the filing.
- Third-quarter device and disposables sales of $92 thousand for the three months ended September 30, 2026, up from $60 thousand in the same quarter of 2025, the filing disclosed.
- Total assets of $1,376 thousand as of September 30, 2026, against total liabilities of $7,514 thousand, resulting in a stockholders' deficit of $6,138 thousand.
- Accumulated deficit reached $159,392 thousand as of September 30, 2026, compared to $157,055 thousand at December 31, 2025.
- 98,187,564 shares of common stock outstanding as of November 11, 2026, up from 86,154 thousand shares at December 31, 2025.
- Short-term convertible debt in default of $1,150 thousand remained unchanged from December 31, 2025 to September 30, 2026, per the filing.
- Net loss attributable to common stockholders of $2,337 thousand for the nine months ended September 30, 2026, reflecting a deemed dividend for warrant exchanges of $510 thousand and preferred stock dividends of $2 thousand.
Guided Therapeutics Financial Results: Nine Months Ended September 30, 2026
According to the Form 10-Q filed November 16, 2026 for the quarterly period ended September 30, 2026, Guided Therapeutics, Inc. (OTC:GTHP) reported a net loss of $720 thousand for the three months ended September 30, 2026, compared to a net loss of $742 thousand for the same quarter in 2025. For the nine-month period, the company reported a net loss of $1,825 thousand versus $1,978 thousand in the prior-year period. The company reported no provision for income taxes in either period.
The filing disclosed total operating expenses of $673 thousand for the third quarter of 2026, compared to $520 thousand in the same quarter of 2025. This included research and development expenses of $204 thousand, sales and marketing expenses of $23 thousand, and general and administrative expenses of $384 thousand in the three months ended September 30, 2026. A loss on remeasurement of deferred compensation conversion liability of $62 thousand was recorded in the third quarter, while the nine-month period reflected a gain of $160 thousand on the same line item. Interest expense for the nine months ended September 30, 2026 was $442 thousand, compared to $433 thousand in the same period of 2025.
The balance sheet as of September 30, 2026 showed cash and cash equivalents of $111 thousand, compared to $63 thousand at December 31, 2025. Total current liabilities stood at $6,934 thousand, including accounts payable of $2,360 thousand, accrued liabilities of $1,369 thousand, and short-term convertible debt in default of $1,150 thousand. The company reported stock subscriptions received in advance of $280 thousand as of September 30, 2026, a figure not present at December 31, 2025. The filing also noted a deemed dividend for warrant exchanges of $510 thousand recorded during the nine-month period ended September 30, 2026, with no comparable amount in the prior-year period.
What Was Disclosed
Guided Therapeutics filed its quarterly report for the period ended September 30, 2026, disclosing a nine-month net loss of $1,825 thousand, a stockholders' deficit of $6,138 thousand, and short-term convertible debt in default of $1,150 thousand, with 98,187,564 common shares outstanding as of November 11, 2026.




Please wait processing your request...